Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients

Karacaoglan V., ADA A. O., Bilgen S., Cetinkaya G. T., Soydas E., Kunak C. S., ...More

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.47, no.2, pp.554-562, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 47 Issue: 2
  • Publication Date: 2017
  • Doi Number: 10.3906/sag-1602-77
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.554-562
  • Keywords: Xenobiotic/drug metabolizing enzymes, TP53, polymorphisms, response to chemotherapy, survival, nonsmall cell lung cancer, GERM-LINE POLYMORPHISMS, GENETIC POLYMORPHISMS, P53 GENE, CODON-72 POLYMORPHISM, TRANSFERASE GENES, CIGARETTE-SMOKING, 2E1 POLYMORPHISM, MDM2 SNP309, ASSOCIATION, RISK
  • Ankara University Affiliated: Yes


Background/aim: The association between polymorphisms of xenobiotic/drug metabolizing enzymes and TP53 and response to chemotherapy and survival of patients with nonsmall cell lung cancer (NSCLC) are limited and inconclusive. In this study, CYP2E1*5B, CYP2E1*6, CYP2E1*7B, GSTO1 (A140D), and TP53 (Arg72Pro) polymorphisms and response to platinum-based chemotherapy and survival in 137 advanced stage NSCLC patients were investigated.